Takeda Signs Option Agreement With Ascentage Pharma For Exclusive License Of Olverembatinib; Potential Third-Generation BCR-ABL TKI For CML And Other Hematological Cancers; License Excludes Mainland China, Hong Kong, Macau, Taiwan, And Russia
Portfolio Pulse from Benzinga Newsdesk
Takeda has signed an option agreement with Ascentage Pharma for the exclusive license of Olverembatinib, a potential third-generation BCR-ABL TKI for CML and other hematological cancers. The license excludes Mainland China, Hong Kong, Macau, Taiwan, and Russia. Takeda will receive the exclusive option to license global rights to Olverembatinib in all other territories. Ascentage Pharma will advance late-stage clinical development of Olverembatinib before Takeda potentially exercises the option.
June 14, 2024 | 12:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Takeda has signed an option agreement with Ascentage Pharma for the exclusive license of Olverembatinib, a potential third-generation BCR-ABL TKI for CML and other hematological cancers. This agreement could significantly enhance Takeda's oncology portfolio if the option is exercised.
The agreement provides Takeda with the potential to enhance its oncology portfolio significantly, addressing unmet needs in CML treatment. The exclusivity in major markets outside of China and other specified regions could lead to substantial revenue growth if the drug proves successful in late-stage clinical trials.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100